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Background
Pharmacological anti-migraine preventive therapies are
widely used to reduce the impact of migraine on quality
of life; nevertheless, they may exhibit incomplete efficacy
and significant side effects. Transcutaneous supraorbital
neurostimulation (tSNS) has been recently proposed for
the treatment of migraine. Moreover, tSNS has been
recently found superior to sham stimulation for episodic
migraine prevention in a randomized trial [1].
Objective
To evaluate both the safety and efficacy of a brief period
of tSNS in a group of patients with migraine without
aura (MwoA). To this end, we used a tSNS medical
device, called Cefaly® (CEFALY Technology, Herstal,
Belgium), approved for use in migraine prevention by
the Food and Drug Administration (FDA) and for sale
in Europe.
Methods
We enrolled 24 consecutive patients with MwoA experi-
encing a low frequency of attacks (≤5 attacks/month),
whom had never taken migraine preventive drugs in the
course of their life. Patients performed a daily supraorbi-
tal high frequency tSNS, for 20 minutes, for two months.
Primary outcome measures were the reduction in
migraine attacks and migraine days per month (p < 0.05).
Secondary outcome measures were the reduction of
headache severity during migraine attacks (by means of
visual analogic scale) and HIT-6 (Headache Impact Test)
rating, as well as in monthly intake of rescue medication
(p < 0.05). Finally, compliance, treatment satisfaction,
and potential adverse effects related to tSNS were
evaluated.
Results
Between run-in and second month of tSNS treatment,
both primary and secondary endpoints were met.
Indeed, we observed a statistically significant decrease in
the frequency of migraine attacks (p < 0.001) and
migraine days (p < 0.001) per month, as well as a reduc-
tion in average pain intensity during migraine attacks
(p = 0.002), HIT-6 rating (p < 0.001), and intake of res-
cue medication (p < 0.001). All patients showed good
compliance levels and no relevant adverse events
occurred during the tSNS period.
Conclusions
In patients with MwoA experiencing a low frequency of
attacks, significant improvements in multiple migraine
severity parameters was observed following a brief period
of high frequency tSNS [2]. Therefore, tSNS may be con-
sidered a valid option for the preventive treatment of
migraine attacks in patients who cannot or are not will-
ing to take daily medications, or in which low migraine
frequency and/or intensity would not require pharmaco-
logical preventive therapies.
Written informed consent to publish was obtained
from the patient(s).
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